Antibody-modified fluorinated nanogel and its preparation method and application

The fluorinated nanogels modified by antibody are prepared by free radical polymerization technology. Combined with Anti-FAP antibodies, the problem of low penetration efficiency of lung inhalation drugs is solved, effective treatment of pulmonary fibrosis is achieved, and side effects are reduced and cost.

CN118557720BActive Publication Date: 2024-11-22SUZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411058136.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-22
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

The prior art is difficult to effectively penetrate the mucus layer of the lung, resulting in low penetration and absorption efficiency of lung inhaled drugs, and the treatment of pulmonary fibrosis lacks efficient and low side effects.

Method used

Anti-FAP antibodies were used to prepare nanogels by free radical polymerization technology, and combined with Anti-FAP antibodies, specifically capture pathogenic exosomes and block the progress of pulmonary fibrosis.

Benefits of technology

It has achieved efficient penetration of the mucus layer and cell membrane of the lungs, evenly distributed in the lung tissue, specifically capture pathogenic exosomes, effectively treat pulmonary fibrosis, and reduce the side effects and costs of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118557720B_ABST
    Figure CN118557720B_ABST
Patent Text Reader

Abstract

The present invention relates to an antibody-modified fluorinated nanogel and a preparation method and application thereof, and belongs to the field of biomedicine technology. The present invention provides an antibody-modified fluorinated nanogel, wherein the antibody-modified fluorinated nanogel comprises a fluorinated nanogel and an antibody; the fluorinated nanogel is obtained by a free radical polymerization reaction initiated by an initiator in the presence of a crosslinker and a surfactant through a polymerization monomer and a fluorinated monomer; the antibody is coupled to the surface of the fluorinated nanogel through copper-free click chemistry. The preparation process of the antibody-modified fluorinated nanogel of the present invention is simple and efficient, and has broad application prospects. The nanogel obtained by the present invention can achieve efficient mucus penetration and uniform lung tissue distribution during lung inhalation, and can block the progression of pulmonary fibrosis by specifically capturing and removing pathogenic exosomes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to an antibody-modified fluorinated nanogel and a preparation method and application thereof. Background Art

[0002] Pulmonary fibrosis is an irreversible interstitial lung disease that occurs when persistent damage leads to hardening and scarring of lung tissue, and is characterized by bronchiectasis, alveolar remodeling, parenchymal fibrosis, and severe impairment of respiratory function. In recent years, with the in-depth study of cell biology and molecular biology, exosomes, as an important medium for intercellular communication, have gradually become a hot topic of research. Exosomes are a class of nanoscale extracellular vesicles with a diameter of 30-150 nanometers, which are secreted by almost all types of cells and can carry a variety of bioactive molecules, including lipids, amino acids, proteins, metabolites, and various types of nucleic acids, and participate in a variety of physiological and pathological processes.

[0003] In the pathological mechanism of pulmonary fibrosis, studies have found that some exosomes can act as carriers of therapeutic molecules to inhibit fibrosis. However, some exosomes carry pro-fibrotic nucleic acids or proteins, spread pathological signals, and regulate epithelial cell aging or fibroblast proliferation and differentiation, which plays a vital role in the rapid development of fibrosis. Therefore, clearing or inhibiting these pro-fibrotic exosomes has become a potential therapeutic strategy.

[0004] In recent years, more and more studies have focused on the potential pathological role of exosomes in various diseases, such as cardiovascular disease, neurological diseases and cancer. Therefore, pathogenic exosomes are also considered to be a promising therapeutic target. By destroying their intact membrane structure or removing them from the body, the progression of the disease can be effectively blocked. For example, photothermal (Biomaterials 2020, 242, 119932.) and photodynamic (Adv Funct Materials 2024, 2404900.) methods have been used to destroy exosomes captured in vivo. In these studies, it has been confirmed that the downregulation of pathogenic exosomes can have a good therapeutic effect. However, direct destruction of the membrane structure of exosomes in vivo may cause the overflow of exosome components and the production of membrane fragments, causing unclear changes in pathological processes and undesirable immune responses. Another treatment strategy is to directly remove pathogenic exosomes from peripheral blood by hemoperfusion (Advanced Science 2023, 10(34), 2304287.). This direct and complete exosome clearance strategy provides a new perspective in anti-tumor metastasis treatment. However, hemoperfusion requires expensive medical equipment and professional technicians, which greatly limits its wide application. In addition, silica nanoparticles functionalized with aptamers can capture carcinogenic exosomes and reduce the level of circulating exosomes through hepatoenterolytic clearance (Nat Commun 2019, 10 (1), 5476.). This in vivo precise identification, capture and clearance of pathogenic exosomes to the small intestine has opened up a new therapeutic angle. However, it is limited to the clearance of exosomes in peripheral blood. Like most of the current related studies, its application in diseases other than tumors remains to be studied.

[0005] In recent years, only two drugs, pirfenidone and nintedanib, have been approved by the FDA for the treatment of pulmonary fibrosis. However, both drugs can only delay the progression of pulmonary fibrosis and are expensive to treat. Due to their oral administration, they may also cause adverse reactions such as gastrointestinal intolerance and liver damage. Therefore, there is currently a lack of treatments for IPF.

[0006] Compared with oral or intravenous injection, pulmonary inhalation therapy can act more directly and efficiently on the lesions of pulmonary fibrosis and reduce systemic side effects. However, pulmonary inhalation requires the delivery of drugs deep into the lungs, and the mucus layer in the airways that naturally protects the lungs from pathogens and impurities also hinders the penetration and absorption of pulmonary inhaled drugs. With the continuous development of nanotechnology, a variety of nanocarrier design strategies have been proven to be able to effectively penetrate the mucus barrier, such as PEG modification, anionic carriers, and zwitterionic carriers. However, other obstacles besides the mucus barrier in pulmonary inhalation drug delivery will also limit its further application, such as the "PEG dilemma" caused by multiple dosing and the low epithelial transport efficiency caused by anionic carriers. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides an antibody-modified fluorinated nanogel and a preparation method and application thereof. The present invention proposes to construct an antibody-modified fluorinated nanogel for pulmonary inhalation by using a free radical polymerization method. The obtained nanogel can achieve efficient mucus penetration and uniform lung tissue distribution during pulmonary inhalation, and can block the progression of pulmonary fibrosis by specifically capturing and removing pathogenic exosomes.

[0008] In order to achieve the above-mentioned invention object, the present invention provides the following technical solutions:

[0009] The first object of the present invention is to provide an antibody-modified fluorinated nanogel, wherein the antibody-modified fluorinated nanogel comprises a fluorinated nanogel and an antibody; the fluorinated nanogel is obtained by a free radical polymerization reaction initiated by an initiator in the presence of a crosslinking agent and a surfactant through a polymerization monomer and a fluorinated monomer;

[0010] The antibodies were coupled to the fluorinated nanogel surface via copper-free click chemistry.

[0011] The amount of the surfactant used can be used to adjust the particle size of the prepared fluorinated nanogel.

[0012] In one embodiment of the present invention, the polymerizable monomer is selected from acrylamide and / or N-(3-aminopropyl)acrylamide.

[0013] In one embodiment of the present invention, the fluorinated monomer is selected from 2-(perfluorobutyl)ethyl methacrylate.

[0014] In one embodiment of the present invention, the cross-linking agent is selected from N, N'-methylenebisacrylamide.

[0015] In one embodiment of the present invention, the surfactant is selected from sodium bis(2-ethylhexyl)sulfosuccinate and / or BRIJ L4 polyoxyethylene lauryl ether.

[0016] In one embodiment of the present invention, the initiator is selected from ammonium persulfate and tetramethylethylenediamine; the amount of ammonium persulfate added is 0.5 wt%~3 wt%, preferably 1 wt%; the amount of tetramethylethylenediamine added is 1 wt%~10wt%, preferably 5 wt%.

[0017] In one embodiment of the present invention, the antibody is selected from Anti-FAP.

[0018] In one embodiment of the present invention, the particle size of the antibody-modified fluorinated nanogel is 80 nm to 90 nm, preferably about 90 nm.

[0019] The second object of the present invention is to provide a method for preparing the antibody-modified fluorinated nanogel, comprising the following steps:

[0020] (1) dissolving a surfactant in an organic solvent to prepare an emulsion to obtain an oil phase; dissolving a polymerizable monomer, a fluorinated monomer and a cross-linking agent in water to obtain an aqueous phase;

[0021] (2) Under nitrogen protection and rapid stirring, the aqueous phase is dripped into the organic phase drop by drop, and a stable nanoemulsion is formed by ultrasound; an initiator is added to initiate free radical polymerization, and a fluorinated nanogel with a cross-linked structure is formed after the reaction;

[0022] (3) mixing dibenzocyclooctene-succinimide ester with the fluorinated nanogel obtained in step (2) in a buffer solution to obtain dibenzocyclooctene-modified fluorinated nanogel; the molar ratio of the dibenzocyclooctene-succinimide ester to the fluorinated nanogel is 1:1 to 30:1, preferably 10:1;

[0023] Mixing 15-azido-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester and the antibody in a buffer solution to obtain an azide-modified antibody;

[0024] The molar ratio of 15-azido-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester to the antibody is 1:1 to 30:1, preferably 10:1;

[0025] (4) The dibenzocyclooctene-modified fluorinated nanogel obtained in step (3) is mixed with the azide-modified antibody to obtain the antibody-modified fluorinated nanogel.

[0026] Dibenzocyclooctene-succinimidyl ester was conjugated to the amino groups on the surface of the nanogel by reacting NHS with the amino groups on the surface of the nanogel, in order to modify the DBCO groups on the surface. 15-Azide-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester was conjugated to the amino groups on the surface of the FAP antibody by reacting NHS with the amino groups on the surface of the FAP antibody, in order to modify the azide groups on the surface. Then the two were conjugated by click chemistry of azide and DBCO.

[0027] In one embodiment of the present invention, the organic solvent is selected from n-hexane.

[0028] In one embodiment of the present invention, in step (3), the buffer solution is a PBS buffer solution.

[0029] In one embodiment of the present invention, in step (4), the molar ratio of the dibenzocyclooctene-modified fluorinated nanogel to the azide-modified antibody is 1:1 to 10:1, preferably 1:4. The reaction conditions are: stirring at 4°C for 2 h to 48 h, preferably 24 h.

[0030] The third object of the present invention is to provide an exosome clearing agent based on antibody capture, comprising the antibody-modified fluorinated nanogel.

[0031] The fourth object of the present invention is to provide the use of the antibody-modified fluorinated nanogel in the preparation of a drug for treating pulmonary fibrosis.

[0032] In one embodiment of the present invention, the drug is administered by inhalation.

[0033] In one embodiment of the present invention, the dosage of the drug is greater than or equal to 10 mg / kg.

[0034] The mechanism of the present invention is: in the pulmonary fibrosis model, activated fibroblasts secrete pathogenic exosomes, and their surfaces specifically and highly express FAP antigens. Pathogenic exosomes promote the proliferation and migration of fibroblasts, while causing aging of alveolar epithelial cells and accelerating the process of fibrosis. The present invention prepares an antibody-modified fluorinated nanogel, which, after inhalation into the lungs, can efficiently penetrate the mucus layer and alveolar epithelial cells, reach deep into the lungs, and be evenly distributed in the lung tissue. The surface-coupled antibody Anti-FAP specifically recognizes and captures pathogenic exosomes, which then enter the blood circulation and are excreted from the body through liver and gallbladder clearance, effectively treating pulmonary fibrosis.

[0035] The above technical solution of the present invention has the following advantages compared with the prior art:

[0036] 1. The present invention provides an antibody-modified fluorinated nanogel and its preparation method and application. The present invention uses inverse emulsion polymerization to prepare a stable and uniform fluorinated nanogel, and the introduced fluorinated monomer can reduce the adsorption of nanogel and mucin, thereby achieving efficient penetration into the lung mucus layer.

[0037] 2. The particle size of the nanogel of the present invention is about 90 nm, and its large specific surface area provides an efficient capture platform for the removal of exosomes (particle size is 30 nm~50 nm). At the same time, its nanoscale particle size is conducive to lung deposition after lung inhalation.

[0038] 3. The positive charge provided by the amino groups on the surface of the nanogel of the present invention and the modified fluorinated monomers can help the nanogel penetrate the lung mucus layer and cell membrane, effectively enhancing the transport of epithelial cells and enabling them to be evenly distributed in the lung interstitium.

[0039] 4. The modification of the Anti-FAP antibody of the present invention can help the nanogel to specifically bind to pathogenic exosomes secreted by activated fibroblasts, thereby achieving efficient exosome capture and clearance.

[0040] 5. The preparation process of the present invention is simple and efficient, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:

[0042] Figure 1 Describes the particle size diagram of the nanogels in Example 1 and Comparative Example 1;

[0043] Figure 2 TEM images of the nanogels in Example 1 and Comparative Example 1;

[0044] Figure 3 The in vitro capture efficiency of nanogels on exosomes in Example 1, Comparative Example 2 and Comparative Example 3;

[0045] Figure 4 The flow scatter plots of the combination of nanogel and magnetic bead-sorted exosomes in Example 1, Comparative Example 2 and Comparative Example 3 and the formation efficiency of the nanogel-exosome complex; wherein A is the flow scatter plot of the combination of nanogel and magnetic bead-sorted exosomes in Example 1, Comparative Example 2 and Comparative Example 3; B is the formation efficiency diagram of the nanogel-exosome complex;

[0046] Figure 5 The images of exosomes captured in nanogels in Example 1, Comparative Example 2 and Comparative Example 3 are shown; wherein A is a graph of exosomes captured in nanogels in Example 1, Comparative Example 2 and Comparative Example 3; and B is a graph of the Pearson coefficient;

[0047] Figure 6 The photobleaching images and quantitative analysis of the nanogels in Example 1 and Comparative Example 1; wherein A is the photobleaching image of the nanogels in Example 1 and Comparative Example 1; B is the quantitative analysis diagram;

[0048] Figure 7 The results of multi-particle tracking experiments of nanogels in mucus in Example 1 and Comparative Example 1; wherein A is a motion trajectory diagram of nanogels in mucus in Example 1 and Comparative Example 1; B is a function diagram of the mean mean square displacement value of nanogels in mucus over time; C is a distribution diagram of the logarithmic value of the effective diffusion rate (Deff) of nanogels in mucus;

[0049] Figure 8 The results of the lung tissue penetration test of the nanogel in Example 1 and Comparative Example 1 are shown in Figure 1; A is the lung tissue penetration graph of the nanogel in Example 1 and Comparative Example 1; and B is the fluorescence intensity graph;

[0050] Fig. 9The experimental results of the distribution of the nanogel in Example 1 and Comparative Example 1 in the five-lobe lung; wherein A is the biodistribution diagram of the nanogel in Example 1 and Comparative Example 1 in the five-lobe lung; B is the semi-quantitative fluorescence intensity diagram of the five-lobe lung in (A);

[0051] Fig.10 The data of mouse weight, lung wet / dry weight ratio and hydroxyproline content in the mouse pulmonary fibrosis model of Example 1, Comparative Example 1 and Comparative Example 3 are shown; wherein A is a graph showing the change of mouse weight in the mouse pulmonary fibrosis model; B is a graph showing the dry weight ratio of mice in the mouse pulmonary fibrosis model; and C is a graph showing the hydroxyproline content of mice in the mouse pulmonary fibrosis model;

[0052] Fig.11 The present invention is a hematoxylin-eosin staining, Masson staining and Sirius red staining section images and their quantitative analysis in Example 1, Comparative Example 1 and Comparative Example 3 in a mouse pulmonary fibrosis model; wherein A is a hematoxylin-eosin staining, Masson staining and Sirius red staining section images in Example 1, Comparative Example 1 and Comparative Example 3 in a mouse pulmonary fibrosis model; B is a quantitative analysis diagram. DETAILED DESCRIPTION

[0053] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0054] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.

[0055] The manufacturers and product numbers of the reagents and materials used in the examples of the present invention are as follows:

[0056] Anti-FAP (Abcam, ab53066); PKH26 dye (solarbio, D0030-0.1ml); PKH67 (solarbio, D0031-0.1ml); CY7-SE (Yuanye, S85505-5mg); DAPI (Biyuntian, C1002); CD9 exosome capture magnetic beads (invitrogen, 10620D); glycine (aladdin, G274229-1kg); BSA (biosharp, bs114-500g); OCT embedding medium (biosharp, bl557a); bleomycin hydrochloride (mce, hy-17565a); pirfenidone (aladdin, P129335-25g); hematoxylin-eosin (Servicebio, GP1031); Masson stain (Servicebio, GP1032) and picrosirius red (Servicebio, GP1033);

[0057] C57Bl / 6J mice (male, 18 g–20 g, 6–8 weeks old) were purchased from Changzhou Cavens Laboratory Animal Co., Ltd.;

[0058] Fibroblasts extracted from the lungs of patients with pulmonary fibrosis were obtained from patients with idiopathic pulmonary fibrosis in the Second Affiliated Hospital of Soochow University;

[0059] The mucus was obtained from cystic fibrosis patients in the Second Affiliated Hospital of Soochow University and was diluted 20 times with PBS buffer solution before use.

[0060] The CAS numbers of the reagents used in the present invention are shown in Table 1 below:

[0061] Table 1

[0062] Reagents CAS Sodium bis(2-ethylhexyl)sulfosuccinate 577-11-7 BRIJ L4 Polyoxyethylene lauryl ether 9002-92-0 Acrylamide 79-06-1 N-(3-aminopropyl)acrylamide 21381-79-3 N, N'-Methylenebisacrylamide 110-26-9 2-(Perfluorobutyl)ethyl methacrylate 1799-84-4 Ammonium Persulfate 7727-54-0 Tetramethylethylenediamine 110-18-9 Dibenzocyclooctene-succinimide ester 1353016-71-3 15-Azido-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester 944251-24-5 Example 1

[0063] Sodium bis(2-ethylhexyl)sulfosuccinate (474 ​​mg) and BRIJ L4 polyoxyethylene lauryl ether (918 mg) were prepared into an emulsion with n-hexane (40 mL) and dried with nitrogen gas for 20 min. Acrylamide (80 mg), N-(3-aminopropyl)acrylamide (72 mg), N, N'-methylenebisacrylamide (43 mg) and 2-(perfluorobutyl)ethyl methacrylate (374 mg) were dissolved in PBS (500 μL) and dried with nitrogen gas for 20 min. Under nitrogen protection and rapid stirring, the aqueous phase was dripped into the organic phase drop by drop and ultrasonicated. Ammonium persulfate (1wt%) and tetramethylethylenediamine (5wt%) were added to initiate free radical polymerization and stirred at 4°C for 2 h under nitrogen protection. The organic solvent was removed by rotary evaporation, and the nanogel was precipitated and washed three times with tetrahydrofuran. After resuspending with PBS, it was washed three times with a 100 kDA ultrafiltration tube to remove unreacted monomers and crosslinkers. The fluorinated nanogels were obtained by freeze drying.

[0064] Anti-FAP was coupled to the surface of the nanogel by copper-free click chemistry. First, the DMSO solution of dibenzocyclooctene-succinimidyl ester was added to the PBS solution of fluorinated nanogel (10 mg / mL, 1 mL), and 15-azido-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester was added to the PBS solution of Anti-FAP (1 mg / mL, 1 mL). After stirring at 4°C for 1 h, the two were dialyzed to remove unreacted small molecules. Subsequently, the dibenzocyclooctene-modified nanogel and the azide-modified Anti-FAP were mixed and stirred at 4°C for 24 h, and washed three times with a 100 kDA ultrafiltration tube to remove free antibodies to obtain antibody-modified fluorinated nanogel.

[0065] Comparative Example 1

[0066] Sodium bis(2-ethylhexyl)sulfosuccinate (474 ​​mg) and BRIJ L4 polyoxyethylene lauryl ether (918 mg) were prepared into an emulsion with n-hexane (40 mL) and dried with nitrogen gas for 20 min. Acrylamide (80 mg), N-(3-aminopropyl)acrylamide (72 mg) and N, N'-methylenebisacrylamide (43 mg) were dissolved in PBS (500 μL) and dried with nitrogen gas for 20 min. Under nitrogen protection and rapid stirring, the aqueous phase was dripped into the organic phase drop by drop and ultrasonicated. Ammonium persulfate (1wt%) and tetramethylethylenediamine (5wt%) were added to initiate free radical polymerization and stirred at 4°C for 2 h under nitrogen protection. The organic solvent was removed by rotary evaporation, and the nanogel was precipitated and washed three times with tetrahydrofuran. After resuspending with PBS, it was washed three times with a 100 kDA ultrafiltration tube to remove unreacted monomers and crosslinkers. The nanogel was obtained by freeze drying.

[0067] The DMSO solution of dibenzocyclooctene-succinimidyl ester was added to the PBS solution of nanogel (10 mg / mL, 1 mL), and 15-azido-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester was added to the PBS solution of Anti-FAP (1 mg / mL, 1 mL). After stirring at 4°C for 1 h, the two were dialyzed to remove unreacted small molecules. Subsequently, the dibenzocyclooctene-modified nanogel and the azide-modified Anti-FAP were mixed and stirred at 4°C for 24 h, and washed three times with a 100 kDA ultrafiltration tube to remove free antibodies and obtain antibody-modified nanogel.

[0068] Comparative Example 2

[0069] Sodium bis(2-ethylhexyl)sulfosuccinate (474 ​​mg) and BRIJ L4 polyoxyethylene lauryl ether (918 mg) were prepared into an emulsion with n-hexane (40 mL) and dried with nitrogen gas for 20 min. Acrylamide (80 mg), N-(3-aminopropyl)acrylamide (72 mg) and N, N'-methylenebisacrylamide (43 mg) were dissolved in PBS (500 μL) and dried with nitrogen gas for 20 min. Under nitrogen protection and rapid stirring, the aqueous phase was dripped into the organic phase drop by drop and ultrasonicated. Ammonium persulfate (1wt%) and tetramethylethylenediamine (5wt%) were added to initiate free radical polymerization and stirred at 4°C for 2 h under nitrogen protection. The organic solvent was removed by rotary evaporation, and the nanogel was precipitated and washed three times with tetrahydrofuran. After resuspending with PBS, it was washed three times with a 100 kDA ultrafiltration tube to remove unreacted monomers and crosslinkers. The nanogel was obtained by freeze drying.

[0070] Comparative Example 3

[0071] Sodium bis(2-ethylhexyl)sulfosuccinate (474 ​​mg) and BRIJ L4 polyoxyethylene lauryl ether (918 mg) were prepared into an emulsion with n-hexane (40 mL) and dried with nitrogen gas for 20 min. Acrylamide (80 mg), N-(3-aminopropyl)acrylamide (72 mg), N, N'-methylenebisacrylamide (43 mg) and 2-(perfluorobutyl)ethyl methacrylate (374 mg) were dissolved in PBS (500 μL) and dried with nitrogen gas for 20 min. Under nitrogen protection and rapid stirring, the aqueous phase was dripped into the organic phase drop by drop and ultrasonicated. Ammonium persulfate (1wt%) and tetramethylethylenediamine (5wt%) were added to initiate free radical polymerization and stirred at 4°C for 2 h under nitrogen protection. The organic solvent was removed by rotary evaporation, and the nanogel was precipitated and washed three times with tetrahydrofuran. After resuspending with PBS, it was washed three times with a 100 kDA ultrafiltration tube to remove unreacted monomers and crosslinkers. The fluorinated nanogels were obtained by freeze drying.

[0072] Performance Study

[0073] (1) The antibody-modified fluorinated nanogel prepared in Example 1 and the nanogel prepared in Comparative Example 1 were resuspended in a PBS buffer solution (pH 7.4), and the particle size of the nanogel was measured by a Malvern Zetasizer particle size analyzer, and its morphology was observed by TEM. The particle size of the antibody-modified fluorinated nanogel prepared in Example 1 and the nanogel prepared in Comparative Example 1 is shown in FIG. Figure 1 TEM images of the antibody-modified fluorinated nanogel prepared in Example 1 and the nanogel prepared in Comparative Example 1 are shown in FIG. Figure 2 As shown. Figure 1 and Figure 2 It can be seen that the nanogel prepared by the present invention is spherical with uniform particle size (about 90 nm).

[0074] (2) Fibroblasts were extracted from the lungs of patients with pulmonary fibrosis and cultured, the culture medium was collected and pathogenic exosomes were extracted by ultracentrifugation, and the exosomes were labeled with PKH26 dye. The antibody-modified fluorinated nanogel of Example 1, the nanogel of Comparative Example 2, and the fluorinated nanogel of Comparative Example 3 were resuspended in PBS buffer solution (the concentration of the fluorinated nanogel was 1 mg / mL), and then mixed with PBS buffer solution of pathogenic exosomes labeled with PKH26 (the concentration of pathogenic exosomes was 0.3 mg / mL), incubated at 37°C for 15 min; centrifuged at 14,000g for 10 min, the precipitate was collected and re-dispersed with PBS buffer solution, and the fluorescence content was measured by an enzyme-labeled instrument. The in vitro capture efficiency of the nanogels obtained in Example 1, Comparative Example 2, and Comparative Example 3 for exosomes is shown in Figure 2. Figure 3As shown; the results show that the capture efficiency of the antibody-modified fluorinated nanogel for exosomes in Example 1 reaches 79%, while the capture efficiency of the nanogels in Comparative Examples 2 and 3 is relatively low.

[0075] (3) Mix the PBS buffer solution (30 μL, 40 μg / mL) of pathogenic exosomes labeled with PKH26 with CD9 exosome capture magnetic beads, shake at 37°C for 15 min, then dilute the mixture to 1 mL with PBS buffer solution and stir at 37°C for 30 min. Add 100 mM glycine and 2% BSA and continue stirring for 30 min. Apply a magnet and wash twice with PBS buffer solution. Add 10% BSA to block for 30 min, apply a magnet and wash twice with PBS buffer solution. Add them to the PBS buffer solution of the nanogel in Example 1, Comparative Example 2 and Comparative Example 3, respectively, and incubate at 37°C for 15 min. After washing with a magnet, analyze with a flow cytometer. The flow cytometric scatter plots of the combination of nanogel and magnetic bead-sorted exosomes in Example 1, Comparative Example 2 and Comparative Example 3 and the formation efficiency of the nanogel-exosome complex are shown in Figure 2. Figure 4 As shown, the results show that the efficiency of the antibody-modified nanogel in Example 1 in forming a complex with exosomes is about 3 times that of the nanogel in Comparative Examples 2 and 3.

[0076] (4) Male C57Bl / 6J mice were intratracheally injected with pathogenic exosomes labeled with PKH67 (400 μg / mL PBS, 50 μL). Ten minutes later, the nanogel solution (1 mg / mL PBS, 50 μL) labeled with Cy7 in Example 1, Comparative Example 2 and Comparative Example 3 was intratracheally injected. The mice were killed 2 hours later, and the lung tissues were collected, washed with PBS buffer solution, embedded in OCT, frozen and sectioned (thickness 10 μm), immersed in pre-cooled acetone (-20 ℃) ​​for 30 minutes, stained with DAPI for 10 minutes, and observed by CLSM and photographed for analysis. The images of exosomes captured in the nanogel in Example 1, Comparative Example 2 and Comparative Example 3 are shown in Figure 2. Figure 5 As shown; the results show that: in Example 1, the antibody-modified fluorinated nanogel co-localizes with the exosomes, and the Pearson coefficient is as high as 0.8, while in Comparative Examples 2 and 3, the co-localization of the nanogel and the exosomes is less.

[0077] (5) The PBS buffer solution (0.5 mg / mL, 20 μL) of the nanogel in Example 1 and Comparative Example 1 was mixed with mucus (80 μL), placed in a culture dish (20 mm in diameter), and incubated at 37 °C for 30 min. The specified area was irradiated with a laser beam (100% laser power, 500 mW) of a confocal microscope (100 s / time) to bleach the fluorescence in the area. Scan and capture images at different time points (0 s, 30 s, 60 s, 90 s, and 120 s). The relative fluorescence intensity in the bleached area of ​​each group was calculated, taking the fluorescence of the unbleached NCs as 100%. The photobleaching images and quantitative analysis of the nanogels in Example 1 and Comparative Example 1 are shown in Figure 2. Figure 6 As shown; the results show that the fluorescence recovery of the antibody-modified fluorinated nanogel after photobleaching in Example 1 is stronger, proving that the fluoroalkane chain enhances the mobility of the nanogel in mucus.

[0078] (6) The PBS buffer solution (0.5 mg / mL, 20 μL) of the nanogel in Example 1 and Comparative Example 1 was mixed with mucus (80 μL), placed in a culture dish (20 mm in diameter), and incubated at 37°C for 30 minutes. The movement of the nanogel was photographed using a confocal microscope, and the movement trajectory of the nanogel was analyzed using Imaris software, and the mean square displacement and effective diffusion rate of the particles were calculated. The results of the multi-particle tracking experiment of the nanogel in mucus in Example 1 and Comparative Example 1 are shown in Figure 2. Figure 7 As shown; the results show that the antibody-modified fluorinated nanogel in Example 1 has a stronger diffusion trajectory, and its average mean square displacement and effective diffusion rate are also significantly greater than those of Comparative Example 1, proving that the fluoroalkane chain enhances the diffusion ability of the nanogel in mucus.

[0079] (7) Male C57Bl / 6J mice were intratracheally injected with PBS buffer solutions (1 mg / mL, 50 μL) of the nanogels in Example 1 and Comparative Example 1. The animals were killed 15 min and 30 min later, respectively. Lung tissues were collected, washed with PBS buffer solution, embedded in OCT, frozen and sectioned (thickness 10 μm), immersed in precooled acetone (-20 ℃) ​​for 30 min, stained with DAPI for 10 min, and observed by CLSM and photographed for analysis. The results of the in vivo lung tissue penetration experiment of the nanogels in Example 1 and Comparative Example 1 are shown in Figure 2. Figure 8 As shown; the results show that the antibody-modified fluorinated nanogel in Example 1 is able to penetrate the mucus and epithelial barriers and is distributed deep in the lungs, while the antibody-modified nanogel in Comparative Example 1 is trapped in the airways.

[0080] (8) Male C57Bl / 6J mice were injected intratracheally with PBS buffer solutions (1 mg / mL, 50 μL) of the nanogels in Example 1 and Comparative Example 1. The animals were killed 60 min later, and the lungs were divided into five lobes, rinsed with PBS, and imaged in vitro. The experimental results of the distribution of the nanogels in Example 1 and Comparative Example 1 in the five lobes of the lung are shown in Figure 1. Fig. 9 As shown; the results showed that the antibody-modified fluorinated nanogel in Example 1 accumulated more in the mouse lungs and was more evenly distributed.

[0081] (9) Male C57Bl / 6J mice were injected intratracheally with bleomycin (2.5 U / kg) to establish a pulmonary fibrosis model. From the 2nd day to the 14th day, the mice were given drugs every three days, including the PBS buffer solution of the nanogel in Example 1, Comparative Example 1 and Comparative Example 3 (10 mg / kg; lung inhalation) and pirfenidone (300 mg / kg; oral administration). On the 14th day, the mice were killed and the lung tissues were collected for analysis. The data of mouse body weight, lung wet / dry weight ratio and hydroxyproline content in the mouse pulmonary fibrosis model in Example 1, Comparative Example 1 and Comparative Example 3 are as follows: Fig.10 As shown; the results showed that compared with Comparative Example 1, Comparative Example 3 and the clinical drug pirfenidone, the body weight and lung wet / dry weight ratio of mice treated with the antibody-modified fluorinated nanogel in Example 1 gradually returned to normal, and the hydroxyproline content decreased, indicating that the degree of fibrosis improved.

[0082] The images of hematoxylin-eosin staining, Masson staining and picrosirius red staining sections and their quantitative analysis results in Example 1, Comparative Example 1 and Comparative Example 3 in the mouse pulmonary fibrosis model are shown in FIG. Fig.11 The slices showed that compared with Comparative Example 1, Comparative Example 3 and the clinical drug pirfenidone, the mice treated with the antibody-modified fluorinated nanogel in Example 1 had less inflammatory infiltration in the lungs, reduced alveolar inflammation, decreased pulmonary interstitial collagen content, and normal alveolar results, indicating that the fibrosis process was significantly alleviated.

[0083] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. Application of an antibody-modified fluorinated nanogel in the preparation of a drug for treating pulmonary fibrosis; The antibody-modified fluorinated nanogel comprises a fluorinated nanogel and an antibody; the fluorinated nanogel is obtained by a free radical polymerization reaction initiated by an initiator in the presence of a crosslinking agent and a surfactant through polymerization monomers and fluorinated monomers; The antibody is coupled to the surface of the fluorinated nanogel via copper-free click chemistry; The fluorinated monomer is selected from 2-(perfluorobutyl)ethyl methacrylate; The surfactant is selected from sodium bis(2-ethylhexyl)sulfosuccinate and / or BRIJ L4 polyoxyethylene lauryl ether; The antibody is selected from Anti-FAP.

2. The use according to claim 1, characterized in that: The polymerizable monomer is selected from acrylamide and / or N-(3-aminopropyl)acrylamide.

3. The use according to claim 1, characterized in that: The cross-linking agent is selected from N, N'-methylenebisacrylamide.

4. The use according to claim 1, characterized in that: The initiator is selected from ammonium persulfate and tetramethylethylenediamine; the addition amount of the ammonium persulfate is 0.5wt%~3wt%; the addition amount of the tetramethylethylenediamine is 1wt%~10wt%.

5. The use according to claim 1, characterized in that: The following steps are involved: (1) dissolving a surfactant in an organic solvent to prepare an emulsion to obtain an oil phase; dissolving a polymerizable monomer, a fluorinated monomer and a cross-linking agent in water to obtain an aqueous phase; (2) Under nitrogen protection and rapid stirring, the aqueous phase is dripped into the organic phase drop by drop, and a stable nanoemulsion is formed by ultrasound; an initiator is added to initiate free radical polymerization, and a fluorinated nanogel with a cross-linked structure is formed after the reaction; (3) mixing dibenzocyclooctene-succinimide ester with the fluorinated nanogel obtained in step (2) in a buffer solution to obtain a dibenzocyclooctene-modified fluorinated nanogel; Mixing 15-azido-4,7,10,13-tetraoxopentadecanoic acid-N-succinimidyl ester and the antibody in a buffer solution to obtain an azide-modified antibody; (4) The dibenzocyclooctene-modified fluorinated nanogel obtained in step (3) is mixed with the azide-modified antibody to obtain the antibody-modified fluorinated nanogel.

6. The use according to claim 1, characterized in that: The drug is administered by inhalation.